Photo of Eric Alexander

When we started seeing a smattering of cases over long-term contraceptive devices used in connection with tubal ligation surgery, we were not surprised.  Plaintiff lawyers have targeted a wide range of contraceptive drugs and devices for decades.  Commentators beyond this Blog have described how this bent affects contraceptive choice and public health.  When we saw

Photo of Michelle Yeary

That seems like it should be an obvious statement.  FDA regulations draw important distinctions between brand drugs and generic drugs.  A manufacturer seeking FDA approval of a new drug must prove safety and efficacy involving expensive and lengthy clinical trials.  Once approved, that drug becomes the reference list drug.  If a manufacture wants to market

Photo of Bexis

Sooner or later we knew it would happen.  The law on general jurisdiction by consent has been developing very favorably – maybe even too favorably.  Since Daimler AG v. Bauman, 571 U. S. 117 (2014), almost every appellate decision (including every state court of last resort and federal circuit court) has rejected general jurisdiction

Photo of Michelle Yeary

This post is from the non-Reed Smith side of the blog.

Dear Readers,

The tone of today’s missive may be slightly more formal than most.  For you see, as a result of binge watching Bridgerton on Netflix, the written word is being narrated in our head by the incomparable Julie Andrews.  We so greatly esteem